Spain at a glance
- Population
- 49.4 million 2025
- Life expectancy at birth
- 83.9 years, 2024
- People aged 65 and over
- 21.6 % of people, 2025
- Health spending per person
- 3,107 US$ per person, 2023
- Doctors
- 4.29 per 1,000 people, 2022
Spain Long-Read Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$187.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $24.7 Mn | — | — |
| 2025 (base) | $30.7 Mn | +$6.0 Mn | — |
| 2026 (forecast) | $38.2 Mn | +$7.5 Mn | +24.3% |
| 2027 (forecast) | $47.5 Mn | +$9.3 Mn | +54.5% |
| 2028 (forecast) | $59.0 Mn | +$11.5 Mn | +92% |
| 2029 (forecast) | $73.4 Mn | +$14.3 Mn | +138.7% |
| 2030 (forecast) | $91.2 Mn | +$17.8 Mn | +196.7% |
| 2031 (forecast) | $113.4 Mn | +$22.2 Mn | +268.8% |
| 2032 (forecast) | $141.0 Mn | +$27.6 Mn | +358.5% |
| 2033 (forecast) | $175.2 Mn | +$34.3 Mn | +469.9% |
| 2034 (forecast) | $217.8 Mn | +$42.6 Mn | +608.3% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Long-read sequencing reads long stretches of DNA in one go, finding complex genetic changes that short-read sequencing can miss.
Key segments of the long-Read Sequencing market include technology (Nanopore Sequencing and HiFi Sequencing) and application (Rare Disease, Structural Variants and Infectious Disease).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the long-Read Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the long-Read Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the long-Read Sequencing market.
The long-Read Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Read Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.
What doctors and scientists are doing in Long-Read Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Spain
Spain
Spain
Spain
Spain
Spain
Digital Health · Spain
Healthcare Services · Spain
Healthcare Services · Spain
Medical Devices · Spain
Digital Health · Spain
Medical Devices · Spain